LifeSiteNews.com

Wednesday February 16, 2005



     

Houston Biotech Company Developing Diabetes Treatments Exclusively from Adult Stem Cells

HOUSTON, February 16, 2005 (LifeSiteNews.com) – In response to the dismal failure of embryonic stem cell research to produce any advances in medical treatment to date despite massive expenditures, some commercial biotechnology companies are turning, often at the insistence of investors and shareholders, to the exclusive development of adult stem cells.

One such company, PharmaFrontiers, based in Texas, specializes in obtaining and using autologous stem cell therapy applications for diabetes, multiple sclerosis and congestive heart failure. Autologous stem cells, those collected from the patient’s flowing blood, are often thought to be less flexible than embryonic cells. Until recently, bone marrow was thought to be the best source of adult stem cells but more evidence is coming forward that stem cells from flowing blood are as easily differentiated as embryo cells.

Patrick Linbeck, a representative of the company said that PharmaFrontiers has developed the technique of harvesting stem cells directly from a patient’s blood. Bone marrow stem cells, he says, are “not cheap, easily obtained or pluripotent.” Linbeck told LifeSiteNews.com, “Pharma’s cells, like embryonic stem cells, have been differentiated into every type of stem cell in the body. Pharma could even have your blood stem cells extracted to produce every major line of stem cells for you.”

Autologous stem cell treatments along with high-dose chemotherapy, has also proved to be successful in treating a variety of cancers, including, Multiple Myeloma, Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma and Breast cancer.

hw

Back to Top Back to Top


SHARE THIS STORY: E-mail  Print  Newsvine  Digg  Reddit  Del.icio.us  Facebook



MORE NEWS: LifeSiteNews.com Home Page  Last 10 Days   Archives   Special Reports

Copyright © LifeSiteNews.com. This work is licensed under a Creative Commons Attribution-No Derivatives License. You may republish this article or portions of it without request provided the content is not altered and it is clearly attributed to "LifeSiteNews.com". Any website publishing of complete or large portions of original LifeSiteNews articles MUST additionally include a live link to www.LifeSiteNews.com. The link is not required for excerpts. Republishing of articles on LifeSiteNews.com from other sources as noted is subject to the conditions of those sources.